Document:

Exhibit 10.2

 

InhiBIkase
Therapeutics COLLABORATIVE RESEARCH AND DEvELOPMENT AGREEMENT

 

THIS COLLABORATIVE
RESEARCH AND DEVELOPMENT AGREEMENT (“Agreement”) is entered into with an effective date as of this 29th
day of February 2012, by and among, on the one hand. Inhibikase Therapeutics, Inc., a Delaware corporation, with offices
located at 3350 Riverwood Parkway. Suite 1927, Atlanta. Georgia (the “Company”) and. on the other hand. Sphaera
Pharma Pte, Ltd., a company incorporated under the laws of Singapore with its registered office at 8 Temasek Boulevard. #22-03
Suntec Tower 3, Singapore 038988 (“Sphaera Singapore”) and Sphaera Pharma Pvt. Ltd., Plot No. 32, Sector 5, IMT
Manesar Haryana 122051, India (“Sphaera India”) (together with Sphaera Singapore, hereinafter referred to as “Sphaera
Pharma”). (Company and Sphaera Pharma shall be referred to individually as a “Party” and collectively as the
 “Parties.”)

 

RECITAlS

 

WHEREAS, Sphaera
Pharma is an integrated drug discovery and development organization

 

WHEREAS, Company
controls certain technology for use in the prevention, diagnosis, treatment or control of human and animal infectious diseases,
particularly relating to the use of a drug approved for human use to block infection by certain bacterial and viral pathogens,
and

 

WHEREAS, the
Parties have determined that the provision of analysis and testing services offered by Sphaera Pharma is of mutual interest and
benefit;

 

NOW THEREFORE,
in consideration of the mutual covenants and promises herein, the receipt and sufficiency of which are hereby acknowledged. Sphaera
Pharma and Company agree as follows.

 

1.            Analysis
and Testing Project.

 

a.           The
Scope of Work. During the Term (as defined below ) of this Agreement, Company hereby engages Sphaera Pharma and Sphaera Pharma
hereby agrees to perform on behalf of Company various analysis, research and testing services (the “Services”) as are
described on that certain attachment entitled “Scope of Work” (the “SOW” or “Project”), which
is attached hereto, made a part hereof and marked as Attachment “A “ Sphaera Pharma shall during the Term promote the
interests of Company and perform the Services timely, faithfully, honestly, diligently, efficiently and professionally. Without
limiting the generality of the foregoing. Sphaera Pharma hereby agrees (hat the Services shall be performed solely and exclusively
by it.

 

b.           Limitation
on Services. In the performance of the Services. Sphaera Pharma shall (i) use those facilities, equipment, supplies and
materials as arc necessary to and solely and exclusively owned by it or provided to it by Company for use in the Project (the “Materials”);
and (ii) engage those of its employees, including the Project Coordinator (as defined below), whose services are required
for the Project on a “need to know” basis, in which he or she shall have (1) assigned to Sphaera Pharma any and
all of his or her rights in intellectual property created or invented during his or her term of Sphaera Pharma employment and (2) agreed
to such other terms and conditions regarding the Services, the Project Improvements and Project Results (as defined below) as are
substantially similar to the terms and conditions of this Agreement, including, without limitation, the provisions of Sections
4, 5 and 6 hereof (the “Project Personnel”).

 

c.           No
Conflicting Obligation. Sphaera Pharma represents and warrants to Company on the Effective Date and on each day of the Term
that its performance of the Services and all other terms and conditions of this Agreement and as a consultant to Company does not
and will not breach any agreement between it and any other Person. Sphaera Pharma has not entered into, and agrees it will not
enter into, any agreement, cither written or oral, that is or shall be in conflict with this Agreement.

 

d.           Pre-Existing
Property. The Parties shall identify in the SOW any and all Pre-Existing Property (as defined below) that may be necessary
or useful to the Project. For purposes of this Agreement, (i) “Pre-Existing Property” shall mean either Pre-Existing
Intellectual Property (as defined below) or Materials (or both), (ii) “Pre-
Existing Intellectual Property” shall mean any and all intellectual property, data or information created, developed, conceived
or invented, whether or not reduced to practice, that is owned or in which rights are held by the Provider; (iii) “Provider”
shall mean the Party who owns or has rights in or is deemed to own or have rights in any and all such Pre-Existing Properly, the
Project Results or Project Improvements (as such terms and phrases are defined in this Agreement) that is delivered or otherwise
made available to the Recipient, and (iv) “Recipient” shall mean the Party who is in receipt of any such property.

 

    

     

    

 

e.           Materials.
All Materials made or to be made available for use in a Project shall be described in the SOW. which description shall include
Provider’s name and the name or nature, amount or volume, source or origin and any and all restrictions, whether contractual,
legal or otherwise, on the use of the Materials.

 

2.            Consideration
for Services.

 

a.           The
Project Fees. For and in consideration for the Services, Company shall pay to Sphaera Singapore (for and on account of the
Services to be performed by either or both of Sphaera Singapore and Sphaera India) the Project Fixed Fees, Project Variable Fees,
Project Milestone Fees and Project Percentage Fees (as each are defined below )(together, the “Project Fees’’)
in accordance with the following terms and conditions

 

i.            Project
Fixed Fee. A fixed fee for the Services as mutually defined in the SOW(s) (the “Project Fixed Fee’’);

 

ii.           Project
Variable Fee. A variable fee for the Service in the mutually agreed amount proportionate to the effort put into any additional
work defined by a Change Order to the SOW

 

iii.          Project
Milestone Fees. In addition to the Project fixed Fees, milestones arc to be paid in the following amounts, the payment of which
is contingent upon achievement of each of the following milestones (the “Project Milestone Fees”):

 

	Milestone Event	Payment
	First dosing of patient in US Phase 1 trial	$250,000
	US Phase 1 trial completion with endpoints met	S500.000
	US Phase 2 trial completion with endpoints met	$875,000
	I DA Approval	S4.000.000

 

iv.          Project
Percentage Fees. A project percentage lees payment equal to a percentage of annual net sales, if any. from the sale of the new
chemical entity described in the SOW (the “NCI”) to an end user by Company or any sublicensee thereof during that period
beginning with the first commercial sale and ending on the earlier to occur of either the fifteenth (15th) anniversary
of such sale or the expiration of the first patent in which claims covering the NCI is issued in the United States (the “Project
Percentage Ice”).

 

	Rate	Amount of Annual Net Sales
	7%	For that portion of annual net sales that are less than or equal to $500 million
	5%	For that portion of annual net sales that are greater than $500 million

 

b.           Sphaera
Singapore As Designated Representative. Sphaera Singapore is hereby irrevocably appointed as representative, agent and attorney-in-fact
for each of Sphaera Singapore and Sphaera India (i) to give and receive notices and communications relating to the transactions
and other matters contemplated by this Agreement, including those relating to the payment of the Project Fees and indemnification
claims, (ii) to make decisions on behalf of each of Sphaera Singapore and Sphaera India with respect to the transactions and
other matters contemplated by this Agreement, and (iii) to lake other actions on behalf of the Sphaera Singapore or Sphaera
India (or both) as contemplated by this Agreement, including the exercise of all rights granted to the Sphaera Singapore or Sphaera
India (or both) under this Agreement. Each of Sphaera Singapore and Sphaera India agree that Company may rely conclusively on the
written instructions or notices delivered to Company by the Sphaera Singapore.

 

c.           Payment
Due Dates. Company will make the Project Milestone Fee payments to Sphaera Singapore for the Services no later than sixty (60)
days alter the achievement by Company of the applicable conditions or milestones as are set forth above. Payment for Project Fixed
Fee and Project Variable Fee will occur as described in the SOW.

 

    -2-

     

    

 

d.           Interest.
In the event that any payment due hereunder is not made when due. any such undisputed payment shall accrue interest beginning on
the first day following (he calendar month to which such payment relates, calculated at an annual rate equal to 3°0.
Such payment when made shall be accompanied by all interest so accrued. Said interest and the payment and acceptance thereof shall
not negate or waive the right of Sphaera Pharma to any other remedy, legal or equitable, to which it may be entitled because of
the delinquency of the payment.

 

e.           Audit
of Records. Company shall maintain complete and accurate records sufficient to enable accurate calculation of the Project Fees
due to Sphaera Pharma under this Agreement. Once a calendar year for the period during which Company is obligated to pay the Project
Fees, Sphaera Pharma shall have the right to select a certified public accountant to inspect, on reasonable notice and during regular
business hours. Company’s records to verify its statements and such payments due pursuant to this Agreement the entire cost
for such inspection shall be borne by Sphaera Pharma, unless there is a discrepancy of under-reporting or underpayment greater
than 10% in any twelve ( 12) consecutive calendar month period, in which case Company shall bear the entire cost of the inspection,
as well as any additional sum that would have been payable to Sphaera Pharma had Company reported correctly, plus interest thereon.

 

3.            Project
Conferences, Reports and Plan Modifications.

 

a.           Project
Conferences. During the Term (as defined below), Sphaera Pharma shall cause its Project Personnel to meet with Company to discuss
and evaluate the progress of the Project at such times, no less often than at the times designated in the SOW or. if not designated,
then monthly and at the termination or expiration of this Agreement. Such meetings may be held virtually, using video conference,
or in person at such other locations as may be mutually agreed. Consistent with the foregoing. Sphaera Pharma shall provide Company
with (i) written progress reports on the Project no less frequently than as shall be provided in the SOW and. if not provided,
then weekly, and (ii) a final written report of the Project submitted to Company no later than forty-five (45) days after
completion of the Project or the termination or expiration of this Agreement, whichever event first occurs (collectively the “Project
Reports”).

 

b.           Facility
Visits. Upon reasonable advance notice, each of Sphaera Singapore and Sphaera India shall permit Company representatives to
visit its respective facilities during normal working hours and with reasonable frequency, to observe Project progress, discuss
the Project with appropriate Project Personnel and inspect and copy records and data relevant to the Project facility visits by
Company shall also be permitted during the records and data retention period described in this Section below During facility
visits. Company may inspect, but shall not be permitted to copy or remove, in whole or in part, any of Sphaera Pharma’s standard
operating procedures (SOPs).

 

c.           Project
Reports and Records. In each Project Report, the Project Coordinator shall describe (i) the Project Results and any and
all of the Services performed by Sphaera Pharma in accordance with the Statement of Work; and (ii) any and all Project Improvements.
Any and all records relating to the Project shall be maintained by Sphaera Pharma for a period of five (5) years following
the last day of the term or for such longer period as may be required by any regulatory authority having jurisdiction over the
sale of the NCI

 

d.           Modification
of SOW. Should Company want to change a SOW or to include additional Services to be provided by Sphaera Pharma. Company shall
propose to Sphaera Pharma such change or other modification in a written amendment thereto (a “Change Order”). If Sphaera
Pharma agrees to such Change Order. Sphaera Pharma will evidence its agreement to such Change Order by countersigning the same.
The SOW as modified by such Change Order shall be binding on the Parties only if signed by all Parties, whereafter such modified
version of the SOW will be deemed to have amended and replaced the prior version thereof

 

4.            Intellectual
Property Rights

 

a.           Ownership.
As between the Parties. Company shall own all right, title and interest in and to Company’s Pre-Existing Property. Project
Results and the Project Improvements. Sphaera Pharma will own right, title and interest in and to Sphaera Pharma’s Pre-existing
Properly

 

    -3-

     

    

 

b.           Definitions.
For purposes of this Agreement, the following terms and phrases shall have the meaning ascribed thereto:

 

i.            “Project
Improvements” shall mean any Intellectual Property conceived or reduced to practice under this Agreement or within scope
of the SOW made a part hereof by one or more employees of Sphaera Pharma that results from or constitutes improvements in or additions
to the Company’s Pre-Existing Property, including, but not limited to. any know-how, inventions, designs, techniques, innovations
or other discoveries, and

 

ii.           “Project
Results” shall mean, without limitation. (1) any discovery, invention, innovation, development, characterization, identification
or selection (including, without limitation, any and all processes, methods, assays, protocols, tests, services, treatments, targets,
products, molecules, cells, proteins, peptides or nucleic acids) and any method of deriving, making, maintaining, using or manufacturing
the same that either (A) is derived from, arises out of or in connection with the use of the Company’s Pre-Existing
Property or performing the Services in accordance with the SOW. or (B) would not. but for the use of Company’s Pre-
Existing Property or performing the Services in accordance with the SOW. have been identified, discovered or developed and rights
thereto (including, without limitation, the Project Deliverables referenced in the SOW and patent applications filed in connection
therewith or patents issued thereon); and (2) any progeny, replication or derivative of Company’s Material, including,
without limitation, the NCE.

 

c.            Assignment
of Rights.

 

i.            Cooperation.
Sphaera Pharma hereby assigns to Company all right, title and interest in any and all Project Improvements and Project Results.
At the request of Company in the event of assignment. Sphaera Pharma shall execute such assignments, documents and other instruments
as may be necessary or desirable to fully and completely assign any Project Improvements and Project Results to Company and to
assist Company in applying for. obtaining and enforcing patents or copyrights or other rights with respect thereto. If Company
requests, at Company’s expense. Sphaera Pharma will provide Company with reasonable assistance to obtain patents covering
any such Project Improvements and Project Results and convey any and all right, title and interest it may have in any such Project
Improvements and Project Results to Company.

 

ii.           If
the Company chooses to not pursue patents for Project Results that otherwise constitute jointly-owned intellectual property derived
during (he Term of this Agreement. Sphaera Pharma reserves the right to file on their own behalf.

 

iii.          If
appropriate under definitions of inventorship. Company and or its scientist(s) shall be listed as co-inventors of the Project
Improvements and Project Results for their participation in the development and execution of the testing plan, procedures and related
protocols.

 

5.            Restrictions
on Disclosure of Confidential Information

 

a.            Definition.
Each of Sphaera Pharma and Company acknowledges that it may be necessary for the Provider to disclose information to the Recipient
(hat is considered by the Provider to be its proprietary or confidential information in order for Sphaera Pharma to perform the
Services relating to a proposed or actual Project. To preserve the proprietary or confidential nature of such information, Sphaera
Pharma and Company agree to either, (i) clearly mark the term “CONFIDENTIAL INFORMATION” upon the information
and forward it only to the Recipient in writing; or (ii) orally disclose Io the Recipient the proprietary or confidential
nature of the information, subsequently indicate the nature of such information contained (herein and in a writing addressed to
the Recipient and clearly mark the writing or information with the term “CONFIDENTIAL INFORMATION” and deliver it to
the Recipient within thirty (30) days of disclosure (all such information so marked or designated being “Confidential Information”),
for purposes of this Agreement, each SOW and any and all information relating thereto, including, without limitation, the Project
Results and Project Improvements shall constitute, as between the Parties, the proprietary and Confidential Information of Company.
with Company being deemed the Provider thereof; and all Sphaera Pharma Pre-Existing Property shall constitute the Confidential
Information of Sphaera Pharma for the purposes of this agreement, the phrase “Trade Secret” shall mean information
(including, but not limited to. Confidential Information) that (y) derives economic value, actual or potential, from not being
generally known to. and not being readily ascertainable by proper means by. other persons who can obtain economic value from its
disclosure or use; and (z) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy.
To the extent that applicable law mandates a definition of “trade secret” inconsistent with the foregoing definition,
then the foregoing definition shall be construed in such a manner as to be consistent with the mandated definition under applicable
law.

 

    -4-

     

    

 

b.            Restrictions.
Without the Provider’s prior written consent. Recipient shall refrain from (i) disclosing or otherwise causing to be
disclosed any of Provider’s Confidential Information for a period of five (5) years from the termination of this Agreement,
provided, however, that in the case of Confidential Information that constitutes a Trade Secret (as defined below’), such
period shall run for the period during which any such information continues to constitute a Trade Secret, and (ii) except
as otherwise provided in the SOW. using any such information for any purpose whatsoever.

 

c.            Recipient’s
obligation of non-disclosure shall not apply to any or all of information that is evidenced by contemporaneously written records
and:

 

i.            is
in the public domain at the time of disclosure;

 

ii.           becomes
part of the public domain alter disclosure through no fault of Recipient;

 

iii.          is
in Recipient’s possession at the time of disclosure or is properly obtained by Recipient from a third party with a valid
legal right to disclose such information and such third party is not under a confidentiality obligation to the Provider;

 

iv.          has
been independently developed by Recipient prior to the Effective Date; or

 

v.           is
required to be disclosed by operation of law, governmental regulation or court order; provided, however. Recipient shall use commercially
reasonable efforts to provide Provider at least 30 days’ notice prior to such disclosure. Recipient further agrees to use
all reasonable effort to cooperate in securing confidential protection for such information; further, provided, that in all cases.
Recipient shall limit strictly any such disclosure to the information that is requested hereunder

 

d.            Publicity
Company shall not use the name of Sphaera Pharma or any Project Personnel in any publicity, advertising, or news release without
the prior written approval of an authorized representative of Sphaera Pharma. Sphaera Pharma shall not use the name of Company
or any employee of Company in any publicity, advertising, or news release, without the prior written approval of Company .

 

e.            Return
of Materials. Upon and coincident with either the termination or expiration of this Agreement, at the election and request
of Provider. Recipient agrees to cither return to Provider or destroy any and all Materials and other Confidential Information,
as well as permanently delete all electronically or otherwise stored Confidential Information from all systems containing such
Confidential Information, and if destruction is requested. Recipient shall provide to Provider a Certificate of Destruction and
Compliance in the form attached as Attachment “C.”

 

f.            Ancillary
Provisions. Sections 4. 5 and 6 of this Agreement, along with the Schedules applicable thereto, shall be construed as an agreement
ancillary to the other provisions of this Agreement and the existence of any claim or cause of action of Sphaera Pharma against
Company, whether predicated on this Agreement or otherwise, shall not constitute a defense to the enforcement by Company of such
Sections.

 

g.            Tolling.
Each Party hereby expressly acknowledges and agrees that in the event the enforceability of any of the terms of Section 6
of this Agreement shall be challenged in court or pursuant to arbitration and the other Party is not enjoined (either temporarily
or permanently) from breaching any of the restraints set forth in this Agreement, then if a court of competent jurisdiction or
arbitration panel finds subsequently that the challenged restraint is enforceable, the time period of the restraint shall be deemed
tolled upon the tiling of the lawsuit challenging the enforceability of the restraint until the dispute is finally resolved and
all periods of appeal have expired.

 

    -5-

     

    

 

6.            Restrictions
on the Use of Provider’s Property

 

a.            In
General. As between the Parties, any and all Pre-Existing Property is and shall constitute and remain for all purposes the
sole and exclusive properly of the Provider.

 

b.            Restriction
on Use Provider’s Property. Except as otherwise expressly provided in this Agreement or the SOW.

 

i.            Recipient
shall limit its use of the Provider’s property (e.g. in the case of Company. Company’s Pre-Existing Property, the Protect
Results and Project Improvements; and. in the case of Sphaera Pharma, Sphaera Pharma’s Pre-Existing Property) (collectively.
the “Project Property”) solely and exclusively to the purposes described in this Agreement and for no other purpose
whatsoever;

 

ii.           no
option, license or other conveyance of rights, express or implied, is granted by Provider to Recipient or any other person, including,
without limitation, any Project Personnel, in connection with any of Provider’s Project Property;

 

iii.          none
of the Provider’s Properly, in whole or in part. (I) may be made or sold, licensed or otherwise transferred to a third
party by Recipient; (2) will be used by Recipient in human subjects, in clinical trials, or for diagnostic purposes involving
human subjects without the prior written consent of Provider; (3) is to be used by Recipient at any location other than at
Recipient’s laboratory or by any individual or other person other than by the Project Personnel; (4) will be used by
Recipient for any purpose, other than as expressly permitted under this Agreement and in compliance with all applicable laws, and
in no event for any commercial or competitive purposes Sphaera Pharma further agrees (hat it shall use Company’s Pre-existing
Property in the configuration in which they are received, may not hinder any circumstance manufacture or transform them to any
other configuration and any such Services will be subject to the rights of third parties, if any. whether under license therefrom
or otherwise and this Agreement and the SOW

 

c.            No
Reverse Engineering. Sphaera Pharma hereby acknowledges that certain of Company’s Preexisting Intellectual Properly and
Confidential Information provided by it to Sphaera Pharma may be encoded or otherwise “cloaked” to protect and maintain
the confidentiality thereof from Sphaera Pharma and. in any such case. Sphaera Pharma agrees to refrain and shall cause each person
acting for and on its behalf, including, without limitation, the Protect Personnel, to refrain from engaging in any act or attempt
to act by which or as a result of which any such Pre-existing Intellectual Property or Confidential Information would be reverse
engineered, decompiled, translated, interpreted, decoded, revealed or otherwise identified.

 

d.            Materials.
The Materials shall be used with prudence and appropriate caution in any experimental work and in compliance with this Agreement,
the applicable SOW and all applicable statutes, regulations and other applicable governmental rules, including, without limitation,
the National Institutes of Health guidelines on the use of animals and recombinant DNA. The Materials may not be used for in vivo
testing in human subjects. Materials derived from human donors may not be transferred with any individual donor-identifying information.
Except as otherwise expressly provided in the SOW, THE MATERIALS ARE PROVIDED WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR
ANY PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED.

 

e.            No
Publication. Notwithstanding any provision of this Agreement to (he contrary, in no event shall Sphaera Pharma have any right
to publish or otherwise use or disclose Company’s Project Property, including, without limitation, the Protect Improvements
and Project Results, without the prior written consent of Company, which consent may be withheld, denied, conditioned or delayed
in Company’s sole and absolute discretion.

 

7.            Indemnification.

 

a.            Sphaera
Pharma Indemnification. Sphaera Pharma shall indemnify Company and each of its affiliates and each director, officer, employee,
agent, representative, successor and assign thereof (the “Company Indemnified Parties”), and defend and hold each of
them harmless, from and against any and all third party claims, lawsuits, losses, damages, liabilities, penalties, costs and expenses
(including reasonable attorneys’ fees and disbursements) (collectively. “Third Party Losses”) incurred by any
of them in connection with, arising from or occurring as a result of (i) the material breach by Sphaera Pharma of any of any
term or condition of this Agreement; (ii) Sphaera Pharma’s negligence, willful misconduct or violation of applicable
law in the performance of this Agreement, and (iii) the enforcement by Company of its rights under this Section 7(a).
except, in each case, for those Third Party losses for which Company has an obligation to indemnify the Sphaera Pharma Indemnified
Parties pursuant to Section 7(b). below, as to which Third Party Losses each Party shall indemnify the other Party to the
extent of its respective liability for such Third Party Losses.

 

    -6-

     

    

 

b.            Company
Indemnification. Company shall indemnify Sphaera Pharma and each of its affiliates and each director, officer, employee, agent,
representative, successor and assign thereof (the “Sphaera Pharma Indemnified Parties”), and defend and hold each of
them harmless, from and against any and all Third Party Losses incurred by any of them in connection with, arising from or occurring
as a result of (i)the material breach by Company of any term or condition of this Agreement, (ii) any violation of applicable
law in the performance of its obligations under this Agreement, and (iii) the enforcement by Sphaera Pharma of its rights
under this Section 7(b). except, in each case, for those Third Party Losses for which Sphaera Pharma has an obligation to
indemnify the Company Indemnified Parties pursuant to Section 7(a). as to which Third Party Losses each Party shall indemnify
the other Party to the extent of its respective liability for such Third Party Losses.

 

8.            Hazardous
Materials.

 

All Materials provided
for use in a Project must be accompanied by the applicable environmental and safely information for those materials as required
by law. The responsibility for and costs of disposal of all Provider Materials remaining at the termination of the SOW will rest
with the Provider. Provider shall arrange for disposal or removal of any remaining Provider Materials prior to receipt of any final
report of the Project. Sphaera Pharma will observe all applicable safety precautions and governmental requirements concerning handling
of lest materials.

 

9.            Independent
Contractor

 

For the purposes of
this Agreement and all services to be provided hereunder, the Parties shall be. and shall be deemed to be. independent contractors
and not agents or employees of the other Party. Neither Party shall have the authority to make any statements, representations
or commitments of any kind or to take any action which shall be binding on the other Party, except as may be expressly provided
herein or authorized in writing.

 

10.            Re-purchase
Option and Development Right. re: Field of Cancer.

 

a.           Abandonment.
Notwithstanding anything set forth in this Agreement, should Company or any successor-in-interest thereof decide in its sole discretion
to abandon the development or commercialization of the NCE that results from the SOW. Company or its successor-in-interest shall
give written notice thereof to Sphaera Pharma (the “Abandonment Notice”). On the thirtieth (30th)
Business Day following the day that the Abandonment Notice was delivered to Sphaera Pharma (the “Repurchase Period”),
Sphaera Pharma shall have the irrevocable right and option to acquire, and upon due exercise of such option, Company or any successor
thereof shall sell to Sphaera Pharma, the NCE to the extent of its unencumbered rights therein and controlled by Company or such
successor.

 

b.           Repurchase
Notice. Sphaera Pharma may exercise its right to purchase the NCI by delivering written notice of the same to Company or successor
thereof at any time during the Repurchase Period (“Repurchase Notice”). Should Sphaera Pharma fail to deliver such
written notice to Company or such successor during the Repurchase Period, the rights of the Sphaera Pharma shall be null and void.

 

c.           Purchase
Price. The purchase price for the NCE shall be an amount equal to the NCEs fair market value at the point in development it
has been taken by Company. The closing of the purchase and sale of NCE shall occur within thirty (30) days following the delivery
of Repurchase Notice, or such other time as Company or such successor and Sphaera Pharma shall mutually agree.

 

    -7-

     

    

 

d.           Condition
to Sale. The obligation of Company or any successor thereof to sell the NCE under this Section to Sphaera Pharma shall
be conditioned on Sphaera Pharma otherwise being in compliance with the terms of this Agreement and delivering at closing a full
and complete general release of any and all claims it may have against Company or any successor thereof and the securing of any
and all necessary third party consent.

 

e.           Development
Right. Inhibikase hereby agrees that Sphaera Pharma will have the right to develop the NCE for use in the treatment of cancer
in humans; provided, however, that Sphaera Pharma shall use commercially reasonable efforts in any such development efforts, undertake
any and all such development activities in compliance with this agreement and applicable standards, guidelines, regulations and
laws, and indemnify and hold harmless Company from any and all damages Company may incur as a result thereof.

 

11.            Notice
of IND Enabling Studies

 

If Company determines
to conduct IND enabling studies, it agrees to notify Sphaera Pharma of such determination, at which time the parties will discuss
whether Sphaera can assist in the advancement of the SOW work product into clinic and. if so, at what cost.

 

12.            Term
and termination

 

a.           Term.
The term of this Agreement shall commence with Effective Date and terminate upon that date which coincides with the last day of
the Term (as defined below ) (such date shall be referred to as the “Expiration Date”); provided. however, that in
no event shall the expiration of this Agreement occur prior to the date on which the obligations by one Party to the other Party
shall have lapsed under any SOW (together, the “Term”), for purposes of this Agreement, the phrase “Term”
shall mean that period from the Effective Date through and including the one hundred and eightieth (180) day thereafter

 

b.           Termination
for Cause. Upon any material breach of this Agreement by a Party (the “Breaching Party”), the other Party (the
 “Non-Breaching Party”) may terminate this Agreement by providing ninety (90) days’ written notice to the Breaching
Party of the occurrence and nature of such material breach. The termination shall become effective at the end of the notice period
unless the Breaching Party cures such breach during the notice period. The Non-Breaching Party may. by notice to the Breaching
Party, designate a later date for such termination in order to facilitate an orderly transition of activities relating to the Product
or Process. Notwithstanding the foregoing, if such breach, by its nature, is curable, but not within the forgoing cure period,
then such cure period shall be extended if the Breaching Party provides a written plan for curing such breach to the Non-Breaching
Party and uses diligent efforts to cure such breach in accordance with such written plan; provided, however, that no such extension
shall exceed one-hundred twenty (120) days without the consent of the Non-Breaching Party; and in the event of a dispute as to
whether performance has been made by either Party pursuant to this Agreement, the relevant cure period with respect thereto shall
be lolled pending resolution of such dispute in accordance with the applicable provisions of this Agreement.

 

c.           Accrued
Rights. Termination or cancellation of this Agreement shall not affect the rights and obligations of the parties accrued prior
to termination.

 

d.           Survival.
Notwithstanding anything to the contrary, as contained herein any provision of this Agreement which by their nature extend beyond
termination or expiration, shall survive such termination or expiration, including but not limited to the provisions of Section 2.
3. 4, 5. 6 and 7.

  

    -8-

     

    

 

13.          Notice.
Any notice required by this Agreement shall be given by registered or certified mail, return receipt requested, addressed in the
ease of Sphaera Pharma to:

 

	 	
        Sphaera Pharma Pte Ltd.

        8 Temasek Boulevard

        #22-03 Suntec Tower 3

        Singapore 038988

        Attn: Dr. Frank Hollinger

	 	 
	With a copy to:	
        Sphaera Pharma Pvt. Ltd.

        Plot No. 32, Sector-5,

        IMT Manesar-122051

        Attn: Abhinav Dhandia, Manager-Corporate
        Affairs & Development

	 	 
	 	or in the case of Company to:
	 	 
	 	
        Inhibikase Therapeutics, Inc.

        3350 Riverwood Parkway

        Suite 1927

        Atlanta, Georgia

        Attn: Milton H. Werner, PhD

	 	 	 

or at such other addresses as may be given from time to lime
in accordance with the terms of this notice provision.

 

14.          Results
of Project

 

Sphaera Pharma will
conduct the Services in accordance with generally-accepted professional standards of workmanship and effort. NEITHER PARTY MAKES
ANY WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND HEREBY
DISCLAIMS ALL SUCH WARRANTIES AS TO ANY MATTER WHATSOEVER, INCLUDING, WITHOUT LIMITATION, WARRANTIES WITH RESPECT TO: (a) THE
PROJECT AND ANY RESULTS OF THE PROJECT; (b) DATA, REPORTS, INFORMATION OR RESEARCH PROVIDED BY SPHAERA PHARMA OR COMPANY;
AND (c) ANY INVENTION OR PRODUCT, OR OWNERSHIP THEREOF, WHETHER TANGIBLE OR INTANGIBLE, TESTED, CONCEIVED, DISCOVERED, OR
DEVELOPED IN THE PROJECT OR IN CONNECTION WITH CONDUCTING THE PROJECT UNDER THIS AGREEMENT.

 

15.          Export
Controls

 

Each party acknowledges
that any information or materials provided by the other under this Agreement may be subject to India and U.S export control laws
and regulations, including the International Traffic in Arms Regulations (“ITAR”, 22 CFR Chapter I, Subchapter M, Parts
120-130), Export Administration Regulations (“EAR”, 15 CIR Chapter VII, Subchapter C, Parts 730 774), and Assistance
to Foreign Atomic Energy Activities (10 CFR Part 810); each party agrees to comply with all such laws.

 

16.          Miscellaneous

 

a.            Neither
Party may assign or otherwise encumber this Agreement in whole or in part or any rights hereunder, without the prior written consent
of the other Party, such consent not to be unreasonably withheld, delayed, conditioned or denied; provided, however, that (a) Company
may assign this Agreement in whole or in part to an affiliate thereof on the condition that Company shall remain liable hereunder
for the prompt payment and performance of all obligations thereof, and to a third party in connection with a sale or transfer by
operation of law of all or substantially all of its business or assets; provided, further, that any such assignment shall in all
events be conditioned on the assignee agreeing to be bound by the terms of this Agreement.

 

b.            Unless
otherwise specified, this Agreement and its Attachments embody the entire understanding between Sphaera Pharma and Company with
respect to the Project, and any prior or contemporaneous representations, cither oral or written, are hereby superseded. No amendments
or changes to this Agreement, including, without limitation, changes to the scope of the SOW. period of performance or budget,
shall be effective unless made in writing and signed by authorized representatives of the Parties.

 

c.            During
the Term and for a period of two (2) years subsequent to the termination of this Agreement. Company shall not. directly, indirectly
or through any other party or means solicit employee (s) of Sphaera Pharma for employment, hiring or engagement as an independent
contractor either under its own employment or in any of its subsidiaries and/or affiliates.

 

    -9-

     

    

 

d.            This
Agreement shall be governed by and construed in accordance with the domestic laws of the State of New York, without giving effect
to any choice or conflicts of law provision or rule. Each of the Parties consents to the exclusive jurisdiction of the Federal
and State Courts or arbitration sitting in New York. New York. USA. in connection with any dispute arising under this Agreement
and hereby waives, to the maximum extent permitted by law. any objection, including any objection based on venue or inconvenient
forum, to the bringing of any such proceeding in such jurisdiction. Subject to the foregoing and except for matters in equity (e.g..
injunctive relief), in the event of any dispute, claim, question, or disagreement arising from or relating to (his agreement or
the breach thereof, the parties hereto shall use their best efforts to settle the dispute, claim, question, or disagreement. To
this effect, they shall consult and negotiate with each other in good faith and. recognizing their mutual interests, attempt to
reach a just and equitable solution satisfactory to both parties. If they do not reach such solution within a period of 60 days,
then, upon notice by either party to the other, all disputes, claims, questions, or differences shall be finally settled by arbitration
administered by the American Arbitration Association in accordance with the provisions of its Commercial Arbitration Rules.

 

[Signature page follows]

 

    -10-

     

    

 

IN WITNESS WHEREOF,
the parties have caused this Agreement to be executed by their duly authorized representatives.

 

	Sphaera Singapore	 	Inhibikase Therapeutics, Inc.
	 	 	 
	/s/ Sundeep Dugar	 	/s/ Milton H. Werner
	Signature	 	Signature
	 	 	 
	Sundeep Dugar	 	Milton H. Werner, Ph.D.
	Printed Name	 	Printed Name
	 	 	 
	President & CEO	 	President & CEO
	Title	 	Title
	 	 	 
	March 2, 2012	 	 
	Date	 	Date
	 	 	 
	 	 	 
	Sphaera India	 	Read and acknowledged by
	Sphaera Pharma Pvt. Ltd.	 	Project Coordinator, Sphaera Pharma:
	 	 	 
	/s/ Abhinav Dhandia	 	/s/ Frank P. Hollinger
	Signature	 	Signature
	 	 	 
	Abhinav Dhandia	 	Frank P. Hollinger, PhD
	Printed Name	 	Printed Name
	 	 	 
	Manager, Corporate Affairs & Development	 	Vice President
	Title	 	Title
	 	 	 
	March 2, 2012	 	March 2, 2012
	Date	 	Date

 

    -11-

     

    

 

Attachment
 “A”

 

SCOPE
OE WORK

 

Subject to the terms of that certain agreement
entitled “Collaborative Research and Development Agreement” entered into by and among, on the one hand. Inhibikase
Therapeutics, Inc., a Delaware corporation, with offices located at 3350 Riverwood Parkway. Suite 1927. Atlanta, Georgia
(the “Company”) and, on the other hand, Sphaera Pharma Pte. Ltd., a company incorporated under the laws of Singapore
with its registered office at 8 Temasek Boulevard, #22-03 Suntec Tower 3, Singapore 038988 (“Sphaera Singapore”) and
Sphaera Pharma Pvt. Ltd. Having registered office at E-375, First Floor, Greater Kailash-11, New Delhi-110048, INDIA (“Sphaera
India”) (together with Sphaera Singapore, hereinafter referred to as “Sphaera Pharma”) (the “Collaborative
Agreement”). Company hereby grants Sphaera Pharma a limited, revocable license to use Company’s Pre-Existing Property
(as described below), which are to be held in trust for Company and used solely and exclusively for research and development by
Sphaera Pharma in accordance with the terms of this SOW and protocols as approved by Company, which testing shall be conducted
by the Project Coordinator and such other Project Personnel as may be employed by Sphaera Pharma (the “Internal Use License”).
Nothing in this Agreement shall be construed to grant to Sphaera Pharma any rights in the Company Project Property, including,
without limitation, the Materials, other than the Internal Use License as expressly provided in this Agreement, or to preclude
Company from any use of or from granting any license for any use of the Materials.

 

Project Overview Modification of
the Abelson tyrosine kinase inhibitor Imatinib to prepare a modified drug with a desired pharmacokinetic properties profile.

 

Project Personnel

 

Project Coordinator:
Dr. Frank P. Hollinger

 

Project Deliverables

 

		1)	Design and synthesize 13 - 15 modified drug analogs of Imatinib to potentially identify compounds
with reduced Cmax and increased Cmin in mice.

 

		(a)	Evaluate compounds for solubility

 

		(b)	Evaluate compounds for stability (solid and in aq. solution)

 

		(c)	Evaluate compounds for conversion to active ingredient (Imatinib)

 

		(d)	Evaluate compounds in mouse or rat PK to determine the PK parameters such as Cmax Cmin
using accepted and approved practices. Use Imatinib as a reference.

 

		(e)	Identify two compounds with the potential for further development efforts.

 

		2)	Proposed compounds subject to their ability to be synthesized:

 

 

    -12-

     

    

 

 

Project Timeline

 

4 -5 months

 

Company’s Pre-Existing Property

 

Pre-Existing Intellectual Property:
Mechanism of action knowledge, use of tyrosine kinase inhibitors against all receptor and non-receptor human tyrosine kinases,
use of imatinib against bacterial and viral pathogens as an anti-infective agent.

 

Sphaera Pharma’s Pre-Existing
Property

 

Pre-Existing Intellectual
Property.

 

		1)	Modified Drug Technology Platform included in but not limited to the patent application entitled
 “Substituted Methylformyl Reagents & Method of using the same to modify Physicochemical and/or pharmacokinetic Properties
of Compounds’’ (application number 1092/DI I 2010).

 

Project Term 180 consecutive calendar
days

 

Project Reports & Milestone
Events:

 

Progress Meetings and
Reports. Quarterly

 

Project Completion.
120 days from the date of signing

 

Project Endpoints: Decrease in serum
Cmax of Imatinib. increase of Cmin in mice or rat to achieve an acceptable profile.

 

Project Fixed Fee: In Lieu of the
services as defined above, the Company agrees to pay a Fixed Fee of USS 160,000 payable over 4 monthly installments to commence
between April 1, 2012 and June I. 2012.

 

Project Variable Fee: No modification
in the Scope of Work, or costs thereof, shall be made unless and until agreed to in writing by both the Parties

 

    -13-

     

    

 

ATTACHMENT
 “B”

 

CERTIFICATE
OF PROJECT COORDINATOR

 

I have read and understood the terms and
conditions outlined in the Collaborative Research and Development Agreement entered into by and among, on the one hand, Inhibikase
Therapeutics, Inc., a Delaware corporation, with offices located at 3350 Riverwood Parkway, Suite 1927, Atlanta, Georgia
(the “Company’’) and, on the other hand, Sphaera Pharma Pte. Ltd., a company incorporated under the laws of Singapore
with its registered office at 8 Temasek Boulevard. #22-03 Suntec Tower 3. Singapore 038988 (“Sphaera Singapore”) and
Sphaera Pharma Pvt Ltd., with its registered offices at E-375, 1st floor, Greater Kailash-2, New Delhi-110048, INDIA
(“Sphaera lndia”) (together with Sphaera Singapore, hereinafter referred to as “Sphaera Pharma”) (the “Collaborative
Agreement”), and the Statement of Work and I agree to abide by them in the capacity of a Project Coordinator in receiving,
using and making a disclosure, if any. of (he Material, the Pre-Existing Intellectual Property. Project Results and Project Improvements,
including, without limitation. Company’s Confidential Information and Trade Secrets and any other intellectual properly or
other tangible property relating thereto. Except as otherwise defined herein, capitalized terms and phrases shall have the meaning
ascribed thereto in the Collaborative Agreement.

 

PROJECT COORDINATOR

 

		By:	 	 

 

    -14-

     

    

 

ATTACHMENT
 “C”

 

(to
be retyped on licensee’s stationary)

 

CERTIFICATE
OF DESTRUCTION AND COMPLIANCE

 

By signing below, I hereby affirm
on behalf of Sphaera Pharma, that:

 

All Material sent to Sphaera Pharma by
Inhibikase Therapeutics, Inc. (the “Company”) (“Company”) and all Project Property made pursuant to
that certain Collaborative Research and Development Agreement and the related SOW, entered into by and among, on the one hand, Inhibikase
Therapeutics, Inc., a Delaware corporation, with offices located at 3350 Riverwood Parkway. Suite 1927, Atlanta, Georgia
(the “Company’’) and, on the other hand, Sphaera Pharma Pte. Ltd., a company incorporated under the laws of Singapore
with its registered office at 8 Temasek Boulevard, #22-03 Suntec Tower 3, Singapore 038988 (“Sphaera Singapore”) and
Sphaera Pharma Pvt. Ltd., having registered office at E-375, First Floor, Greater Kailash-11, New Delhi-110048, India (“Sphaera
lndia”) (together with Sphaera Singapore, hereinafter referred to as “Sphaera Pharma”) (the “Agreement”),
have been returned to Company or. at Company’s prior written request, destroyed in accordance with Company’s instructions

 

Sphaera Pharma holds no Company Project
Properly at the present time, including, without limitation, the Pre- Existing Intellectual Properly and Materials; and

 

All Project Properly sent to Sphaera Pharma
by Company pursuant to the Agreement to which this Attachment is attached have been used by Sphaera Pharma in full compliance with
the terms and conditions the Agreement, and all work or cooperation contemplated by the SOW has been completed or terminated, and
Sphaera has no further rights thereunder.

 

Except as otherwise defined herein, capitalized
terms and phrases shall have the meaning ascribed thereto in the Agreement.

 

	Sphaera Singapore	 
	 	 
	Sphaera Pharma Pte. Ltd.	 
	 	 
	By:	 	 
	 	 
	Name:	 	 
	 	 
	Title:	 	 
	 	 
	Date:	 	 
	 	 
	Sphaera India	 
	 	 
	Sphaera Pharma Pvt. Ltd.	 
	 	 
	By:	 	 
	 	 
	Name:	 	 
	 	 
	Title:	 	 
	 	 
	Date:	 	 

 

    -15-Exhibit 10.3

 

iNHiBIKASE
THERAPEUTICS

 

FIRST
AMENDMENT TO

COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT

 

THIS
FIRST AMENDMENT TO THE COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (“Agreement”) is entered into with
an effective date as of the 5th day of October 2012 (the “Amendment Effective Date”) by and among, on the
one hand, Inhibikase Therapeutics, Inc., a Delaware corporation, with offices located at 3350 Riverwood Parkway, Suite 1927, Atlanta,
Georgia (the “Company”) and, on the other hand, Sphaera Pharma Pte. Ltd., a company incorporated under the laws of
Singapore with its registered office at 8 Temasek Boulevard, #22-03 Suntec Tower 3, Singapore 038988 (“Sphaera Singapore”)
and Sphaera Phanna Pvt. Ltd., with its registered office at E-375, First Floor, Greater Kailash-II, New Delhi-110048, INDIA (“Sphaera
India”)(together with Sphaera Singapore, hereinafter referred to as “Sphaera Pharma”). (Company and Sphaera Pharma
shall be referred to individually as a “Party” and collectively as the “Parties.”) Except as otherwise
provided in this Agreement, capitalized terms and phrases shall have the meaning ascribed thereto in the Original Agreement (as
defined below)

 

RECITALS

 

WHEREAS,
Sphaera Pharma and Company entered into that certain Collaborative Research and Development Agreement as of the 29 day
of February 2012 (the “Original Agreement”) to address, among other things, certain issues relating to the Company
Compounds (as defined below);

 

WHEREAS,
since having entered into the Original Agreement, each of Sphaera Phanna and Company agreed to file the Joint Applications
(as defined below) on the Company Compounds and Sphaera Compounds (as defined below);

 

 

 

	WHEREAS,
each of the Parties desire to enter into this Agreement for the purpose of amending the Original Agreement to address, among other
things, the Parties' relative rights to the Joint Applications;

 

NOW
THEREFORE, in consideration of the mutual covenants and promises herein, the receipt and sufficiency of which are hereby
acknowledged, Sphaera Pharma and Company agree as follows:

 

1.                 
Amendment. Each of Sphaera Pharma and Company hereby agree that the Original Agreement is and shall be amended by adding
at the end of Section 4 the following provisions in sequential order thereto:

 

a.                  
The Joint Applications. Sphaera Pharma and Company jointly filed intellectual property under application number 61/709704
in the United States on 4 October, 2012 and under application number 3105/DEL/2012 in India on 4 October, 2012 (“the Joint
Applications”). The intellectual property covered by the Joint Applications as filed in the United States and India includes
a series of novel compounds. The representative novel compounds covered by the Joint Applications appear in Table 1 thereto (“Table
1”).

 

     

     

    

 

b.                 
The Company Compounds. Under and for purposes of the Original Agreement, specifically compounds 101 thru 113 of the
isomer represented by Formula III described on Table 1 (hereinafter the “Company Compounds”) constitute Project Results
and/or Project Improvements (as such phrases are defined under the Original Agreement) and, as a result thereof, the sole and exclusive
property of Company, with any and all right title and interest in and to the Company Compounds and all methods and compositions
relating specifically to such Company Compounds being both subject to the terms of the Original Agreement and hereby assigned to
Company.

 

c.                  
The Sphaera Compounds. All other compounds envisioned, implied or subsumed within the Joint Application as isomers
represented by Formula III or Formula IV, including compounds 114 thru 120 described on Table 1, are not subject to the Original
Agreement, but are owned by Sphaera (hereinafter, the “Sphaera Compounds”), with any and all right, title, and interest
to the Sphaera Compounds being held by Sphaera Pharma.

 

d.                 
Patent Ownership and Cooperation.

 

i.                   
The Mixed Patents. The Parties agree that the Mixed Patents (as defined below), including, without limitation, the Joint
Applications, will be jointly owned by both Parties.

 

ii.                 
Cooperation. Sphaera Pharma and Company therefore agree to cooperate in good faith to conduct prosecution of any patent
applications claiming priority to the Joint Applications to obtain patents, to be solely owned by Company, that specifically claim
inventions related to the Company Compounds (as represented by, for example, claim 22 of 61/709704, solely to the extent that A
is a moiety selected from 101-113, and claims 25-27 and 29-36 solely to the extent they depend from claim 22 and where A
is a moiety selected from 101-113), to the extent requested by Company and to the extent reasonably practicable, on a jurisdiction-by-jurisdiction
basis, without negatively impacting Sphaera Pharma’s ability to protect inventions related to the Sphaera Compounds. Ownership
of any other patent applications claiming priority to the Joint Applications shall be determined according to inventorship as determined
under U.S. law. With respect to the Joint Applications and any patents and patent applications arising from or claiming priority
to the Joint Applications and whose claims encompass both Company Compounds and Sphaera Compounds (“Mixed Patents”),
the Parties agree to cooperate in good faith in prosecution, enforcement, and other activities relating to the Mixed Patents and
to the commercialization of Company Compounds and Sphaera Compounds. Sphaera Pharma and Company agree to exchange materials, know-how
and to act jointly to collect data useful to support the specification of the Joint Applications prior to September 15,2013.

 

e.                  
Cross Licenses.

 

i.                   
By Sphaera Pharma. Sphaera Pharma grants to Company an exclusive (even as to Sphaera), worldwide, royalty-free, fully paid-up
license to the Mixed Patents and any and all know how and materials controlled by Sphaera Pharma relating thereto and useful in
the practice thereof to make, Develop, use, sell, offer to sell, and otherwise exploit Company Compounds and related compositions
and methods for the period commencing with the Amendment Effective Date and ending on the later to occur of the expiration of the
last valid claim covering Company Compounds and related compositions and methods or the 15th anniversary of the Amendment
Effective Date; provided, however, that such license is subject to Section 10 of the Original Agreement.

 

    -2-

     

    

 

ii.                 
By Company. Company grants to Sphaera Pharma an exclusive (even as to Company), worldwide, royalty-free, fully paid-up license
to the Mixed Patents and any and all know how and materials controlled by Company relating thereto and useful in the practice thereof
to make, Develop, use, sell, offer to sell, and otherwise exploit Sphaera Compounds and related compositions and methods for the
period commencing with the Amendment Effective Date and ending on the later to occur of the expiration of the last valid claim
covering Company Compounds and related compositions and methods or the 15th anniversary of the Amendment Effective Date
(the “Term”); provided, however, that Sphaera Pharma hereby grants to Company a right of first offer to license
for the Term exclusively under the Mixed Patents and know-how and materials relating thereto and useful in the practice thereof
from Sphaera Pharma the right to make, use, sell, offer to sell, and otherwise exploit any such Sphaera Compound and related compositions
and methods only within the field of infectious disease, the terms of which license both parties agree to use commercially reasonable
efforts to negotiate in good faith and which shall be on customary terms and conditions for licenses of similar intellectual property.
To the extent Company wishes to obtain a license to the Mixed Patents to make, use, sell, or offer to sell any of the Sphaera Compounds
(i.e., compounds 114-120 of Table 1, or any other compound envisioned, implied or subsumed within the applications 61/709704
in the United States and 3105/DEL/2012 in India filed on 4 October, 2012, other than the Company Compounds), such a license will
require an agreement and acceptance by Sphaera Pharma; for purposes of such license, the financial terms and conditions thereof
shall be negotiated by the parties, with Article 2, entitled “Consideration of Services,” of the Original Agreement
having applicability to only the Company Compounds. For the purpose of clarity, except as otherwise provided in this Section (e)(ii),
Sphaera Pharma may use the Sphaera Compounds outside the scope of the Original Agreement without restriction and without any further
approval or agreement from Company.

 

f.                   
No Overlap in Commercial Pursuits.

 

i.                   
Section 10(e) of the Original Agreement provides, in pertinent part, “that Sphaera Pharma will have the right to develop
the Company Compounds for use in the treatment of cancer in humans,” but as provided in Section 10(a) may not commercialize
any of the Company Compounds until and unless Company delivers an Abandonment Notice (as defined in the Original Agreement) and
otherwise complies with Section 10 thereof. Subject to the foregoing, Section 10(e) is hereby amended (but is not otherwise modified)
to add as the last sentence thereof the following:

 

“(a) Company shall neither
undertake to Develop nor Develop or, if in the process of Developing, shall cease developing any one of the Company Compound for
which Company is notified in writing by Sphaera Pharma that Sphaera Pharma has filed an IND on such Company Compound for a cancer
indication in humans, and (b) Sphaera Pharma shall neither undertake to Develop nor Develop or, if it in the process of Developing,
shall cease Developing any Company Compound for which Sphaera Pharma is notified in writing that an IND has been filed for such
Company Compound, which limitation shall remain in effect for the period during which such Development remains continuously active.
As such, each of the Parties agrees to provide to the other written notice of it determining to both (y) choose as a lead candidate
for Development one of the Company Compounds and, as a result thereof, (z) commence IND-enabling studies for the purpose of filing
an IND, which notice shall be delivered to the other Party within ten (10) consecutive calendar days of any such determination.
For purposes of this section, “Development” or “Develop” shall mean those activities relating to non- clinical
and clinical research and drug development, including, without limitation, toxicology, pharmacology and other discovery efforts,
test method development and stability testing, process development, formulation development, delivery system development, quality
assurance and quality control development, statistical analysis, clinical studies or trials (including pre-approval studies and
investigator sponsored clinical studies or trials), regulatory affairs and clinical study or trial regulatory activities (excluding,
however, regulatory activities directed to obtaining pricing and reimbursement approvals and activities constituting manufacturing,
marketing, sales, distribution or other commercialization); and “IND” shall mean an investigational new drug application
filed with the U.S. Food and Drug Administration (“FDA”) or any equivalent filing with any governmental agency having
regulatory authority similar to that of the FDA for a jurisdiction other than the U.S.”

 

 

ii.                 
Unless and until expansion of the Original Agreement is executed between the parties, Company cannot and will not pursue
any development of the Sphaera Compounds 114-120 of Table 1.

 

    -3-

     

    

 

2.                 
Binding and Enforceable Agreement; Entirety of Agreement. The terms of this Agreement shall be binding upon,
and shall inure to the benefit of each of the Parties hereto and their respective successors, heirs and assigns. This Agreement
shall be considered an integral part of the Original Agreement and shall be binding upon each Party from the date first above written.
Subject only to the modifications referred to in this Agreement, the Original Agreement shall remain in full force and effect and
where necessary shall be read and construed and be enforceable as if the terms of this Agreement were inserted therein.

 

3.                 
Fulfillment of Original Agreement.

 

a.                  
Each of the Parties hereby acknowledges that the Services as contemplated under the Original Agreement have been completed
and as of the Amendment Effective Date are terminated; except, however, that Company remains obligated to fulfill
its financial obligations agreed to under Section 2 of the Original Agreement More specifically, as of the date hereof, the Project
Fixed Fee (as defined under the Original Agreement) equals in total the amount of SI60,000 for the synthesis and analysis of Company
Compounds remain due and payable by Company. Each Party hereby acknowledges that the Project Variable Fees have been paid in full.

 

b.                 
Failure by Company to pay the Project Fixed Fees by the first anniversary of the Amendment Effective Date may constitute
grounds for termination of the Original Agreement in accordance with Article 12 thereof, but shall not otherwise affect the rights
of the Parties as described thereunder or under this Agreement.

 

4.                 
Counterparts. This Agreement may be executed in several counterparts, each of which shall be deemed an original,
but together they shall constitute one and the same instrument.

 

[Signatures continued on next page.]

 

    -4-

     

    

 

IN WITNESS WHEREOF,
the parties have caused this Agreement to be executed by their duly authorized representatives.

 

	Sphaera Singapore

Sphaera Pharma Plc. Ltd.	 	Inhibikase Therapeutics, Inc.
	 	 	 
	/s/ Sundeep Dugar  	 	/s/ Milton H. Werner  
	Signature  	 	Signature  
	 	 	 
	Sundeep Dugar, PhD	 	Milton H. Werner, PhD
	Printed Name	 	Printed Name
	 	 	 
	President & CEO	 	President & CEO
	Title	 	Title
	 	 	 
	April 12, 2013    	 	April 5, 2013
	Date	 	Date
	 	 	 
	Sphaera India

Sphaera Pharma Pvt. Ltd.	 	Read and acknowledged by

Project Coordinator, Sphaera Pharma:
	 	 	 
	/s/ Abhinav Dhandia  	 	/s/ Frank P. Hollinger  
	Signature  	 	Signature  
	 	 	 
	Abhinav Dhandia

Printed Name  	 	Frank P. Hollinger, PhD

Printed Name
	 	 	 
	Assoc. Dir – Corporate

Affairs & Business Dev.

Title  	 	Vice President

Title  
	 	 	 
	April 11,2013  	 	April 6, 2013  
	Date  	 	Date  

 

    -5-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]